Antihemophilic Factor Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 250, 500, 1000, 1500, 2000 IU
Reference Brands: Advate (USA), Afstyla (USA), Helixate FS (USA)
Category:
Blood Disorder
Antihemophilic Factor (Factor VIII) is a blood-clotting protein used to treat and prevent bleeding episodes in individuals with Hemophilia A, a genetic disorder where the body lacks sufficient Factor VIII. It works by temporarily raising plasma levels of Factor VIII, enabling proper blood coagulation.
Antihemophilic Factor is available in Injection
and strengths such as 250, 500, 1000, 1500, 2000 IU.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Antihemophilic Factor is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Antihemophilic Factor can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Antihemophilic Factor (AH), also known as Factor VIII, is a crucial protein in the blood coagulation cascade, available in both plasma-derived and recombinant forms. It plays a central role in promoting normal clot formation in individuals with hemophilia A, a genetic disorder characterized by Factor VIII deficiency. The recombinant form of Antihemophilic Factor exhibits full coagulation-promoting activity, making it effective for preventing and controlling bleeding episodes.
Mechanistically, Antihemophilic Factor binds to Factor IXa in the presence of calcium ions and phospholipids, forming a complex that activates Factor X into Factor Xa. This activated complex subsequently converts prothrombin into thrombin, which then cleaves fibrinogen to form fibrin strands. The formation of fibrin ultimately stabilizes the blood clot, effectively controlling bleeding.
Antihemophilic Factor is indicated for the treatment and prophylaxis of bleeding episodes, as well as for surgical interventions in hemophilia A patients. Its recombinant form offers the advantages of high purity, consistent activity, and reduced risk of viral contamination compared to plasma-derived products. It is administered via intravenous infusion under the supervision of trained healthcare professionals, ensuring precise dosing and effective hemostatic control.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing